about
Pulmonary manifestations of antisynthetase syndromeFlushing the central venous catheter: is heparin necessary?Advances in therapeutic interventions for patients with pulmonary arterial hypertensionDiagnosis and Classification of 17 Diseases from 1404 Subjects via Pattern Analysis of Exhaled MoleculesPulmonary hypertension due to left heart disease.BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysisHeritable pulmonary arterial hypertension with elevated pulmonary wedge pressure.[Treatment of pulmonary arterial hypertension].Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension.N-acetylcysteine improves established monocrotaline-induced pulmonary hypertension in ratsAbsence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension.Comparative Safety and Tolerability of Prostacyclins in Pulmonary Hypertension.Maldi-tof fingerprinting of seminal plasma lipids in the study of human male infertility.Hyaluronidase alters the lipid profile of cumulus cells as detected by MALDI-TOF MS and multivariate analysis.Increased oxidative stress and severe arterial remodeling induced by permanent high-flow challenge in experimental pulmonary hypertension.Dexamethasone induces apoptosis in pulmonary arterial smooth muscle cells.A morphometric study of mucins and small airway plugging in cystic fibrosis.Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations.Pulmonary Hypertension Complicating Fibrosing MediastinitisEndothelial cell dysfunction and cross talk between endothelium and smooth muscle cells in pulmonary arterial hypertension.Nuclear factor κ-B is activated in the pulmonary vessels of patients with end-stage idiopathic pulmonary arterial hypertension.Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension.A novel channelopathy in pulmonary arterial hypertension.Therapeutic advances in pulmonary arterial hypertension.Relation between inflammation and symptoms in asthma.A critical role for p130Cas in the progression of pulmonary hypertension in humans and rodents.HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era.Genome-wide association analysis identifies a susceptibility locus for pulmonary arterial hypertension.Pulmonary veno-occlusive disease: recent progress and current challenges.Pharmacokinetic evaluation of continuous intravenous epoprostenol.Pulmonary veno-occlusive disease: the bête noire of pulmonary hypertension in connective tissue diseases?Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension.Pulmonary veno-occlusive disease: advances in clinical management and treatments.Treatment of pulmonary arterial hypertension with targeted therapies.Cellular microparticles in the pathogenesis of pulmonary hypertension.Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis.Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment.Drugs induced pulmonary arterial hypertension.Drug-induced pulmonary arterial hypertension: a recent outbreak.Tyrosine kinase inhibitors in pulmonary arterial hypertension: a double-edge sword?
P50
Q26800639-76EBE4AF-2093-4C76-A25B-591DEDDAAA2BQ26861512-2A938006-02DC-4954-9557-69234F21E0ECQ28085443-5AAAE9F2-C22A-4A32-B0A5-76A1704864F1Q28818128-E2C9276D-506B-411B-9134-884785BA724BQ30234792-D96779C0-907A-4094-8482-19F786A72342Q31038854-CB882F3B-F8A0-423B-9201-A1C41DF959E3Q33161695-DE0E57C1-3F16-4AB1-B7AB-EB6C07AA007AQ33164660-75FCEEC7-4D06-44BA-8BEB-50E661C058D8Q33329056-D65627F9-EEB0-464A-A1AF-9E3032D051ADQ33786092-36F953DE-98F0-4FD4-8F9C-DD7EC8B120DEQ33968765-333820E8-2125-4A84-A8EA-3DDD1BE25CDEQ34508259-1DD2D771-659F-4F49-BA49-739C8AF58688Q35189169-EEF54DE4-899C-42B8-B6EF-21BAB94C1F79Q35213328-91BE73DC-5861-4704-8F5B-C775B6AFC3E1Q35289907-5AEDDBD0-F3D4-49CA-A726-4FEBD573D324Q35779717-777A6A8A-4A97-4CAF-84FF-794FF4A714D1Q36203213-A81DE529-9A6B-4B83-8A5A-7BB8BA5FF4B4Q36825039-08742752-E29B-4357-8F95-6840D319BD7BQ37026122-5AD81F65-CA92-4355-823E-73B281E18646Q37209074-B8E0ECD7-F26F-4F29-824F-29E096B58288Q37215728-5AD5CE42-EC1D-4419-8022-29C2DFECB1BDQ37217507-32100C7A-F7C4-4CF1-9F30-F1A0E0474174Q37219463-3E9AE3AE-8CA7-425F-8DEB-404AB9837BB9Q37362631-49A56961-2639-478F-AD18-8EC46A0E4018Q37390813-2027944F-EC11-48B6-A444-4032DCC6C0E9Q37410202-B04F5C24-25D9-4887-A91F-24FF8248E13BQ37601234-403EB255-093E-460D-A66F-4D6B628E41F9Q37698113-1EE0AE1E-2249-4213-8339-2077A6E8DF2FQ37747995-637CC48F-D81E-4BA5-95E6-47B63699127AQ37809538-880A96C9-7145-4049-8C27-381BD15A5130Q37826548-142FB0D7-DE5A-4A41-AB3C-DEBD4E82A726Q37866804-A3F811FF-A25C-4923-BF65-1A0C27AEB642Q37867672-8B3103A0-A173-4B02-92EC-C469B5237459Q37902509-39E625FC-3C2B-4D34-B856-B3D2E308EA04Q38069139-9F0A4C60-57E2-493A-BC69-F76D4FAD8108Q38112387-783D21EA-2036-42DE-8B5B-56A93BA60AF4Q38128886-6D06DDF7-EF7A-4718-BB80-7052BC46E5B7Q38131111-7D89653B-F90B-45BC-9D2F-06087F88B7EDQ38133491-17C38881-5203-42B9-B8B0-5193FFF6F52BQ38137789-220EE420-BF9A-490C-AC89-D793B061FF58
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
David Montani
@ast
David Montani
@en
David Montani
@es
David Montani
@nl
David Montani
@sl
type
label
David Montani
@ast
David Montani
@en
David Montani
@es
David Montani
@nl
David Montani
@sl
prefLabel
David Montani
@ast
David Montani
@en
David Montani
@es
David Montani
@nl
David Montani
@sl
P108
P214
P106
P108
P21
P213
0000 0000 0260 5362
P214
P31
P3829
P496
0000-0002-9358-6922
P569
1976-10-14T00:00:00Z
P735
P7859
viaf-71698822